MX2023002004A - Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. - Google Patents

Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.

Info

Publication number
MX2023002004A
MX2023002004A MX2023002004A MX2023002004A MX2023002004A MX 2023002004 A MX2023002004 A MX 2023002004A MX 2023002004 A MX2023002004 A MX 2023002004A MX 2023002004 A MX2023002004 A MX 2023002004A MX 2023002004 A MX2023002004 A MX 2023002004A
Authority
MX
Mexico
Prior art keywords
sup
methods
compositions
cns disorders
treating cns
Prior art date
Application number
MX2023002004A
Other languages
English (en)
Inventor
Francesco G Salituro
Albert Jean Robichaud
Boyd L Harrison
Daniel La
Maria Jesus Blanco-Pillado
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2023002004A publication Critical patent/MX2023002004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/002—Expansion of ring A by one atom, e.g. A homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C307/00—Amides of sulfuric acids, i.e. compounds having singly-bound oxygen atoms of sulfate groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C307/02—Monoamides of sulfuric acids or esters thereof, e.g. sulfamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/19—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/385—Saturated compounds containing a keto group being part of a ring
    • C07C49/487—Saturated compounds containing a keto group being part of a ring containing hydroxy groups
    • C07C49/507—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic
    • C07C49/513—Saturated compounds containing a keto group being part of a ring containing hydroxy groups polycyclic a keto group being part of a condensed ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J61/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/004—Expansion of ring B by one atom, e.g. B homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/006—Expansion of ring C by one atom, e.g. C homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/40—Ortho- or ortho- and peri-condensed systems containing four condensed rings
    • C07C2603/42—Ortho- or ortho- and peri-condensed systems containing four condensed rings containing only six-membered rings

Abstract

Compuestos de la Fórmula (I-I): (ver Fórmula) (I-I) y sus sales farmacéuticamente aceptables, donde t, R7, R3, R9, R6a, R6b, R11a, R11b, R15a, R15b, R16a, R16b, R17a, R17b, R18a, R18b, R19a, R19b, R5a, R5b, R8 y R13 tienen los valores que se definen en la memoria descriptiva. Composiciones farmacéuticas que comprenden un compuesto de Fórmula (I-I) y métodos para usar los compuestos, por ejemplo en el tratamiento de trastornos relacionados con el sistema nervioso central.
MX2023002004A 2017-12-22 2020-07-13 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. MX2023002004A (es)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201762610067P 2017-12-22 2017-12-22
US201762612070P 2017-12-29 2017-12-29
US201762611977P 2017-12-29 2017-12-29
US201762612067P 2017-12-29 2017-12-29
US201762612164P 2017-12-29 2017-12-29
US201862765164P 2018-08-17 2018-08-17
US201862728499P 2018-09-07 2018-09-07
US201862737559P 2018-09-27 2018-09-27
US201862754977P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
MX2023002004A true MX2023002004A (es) 2023-02-27

Family

ID=65234664

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020006608A MX2020006608A (es) 2017-12-22 2018-12-21 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023002006A MX2023002006A (es) 2017-12-22 2020-07-13 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023002004A MX2023002004A (es) 2017-12-22 2020-07-13 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020006608A MX2020006608A (es) 2017-12-22 2018-12-21 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023002006A MX2023002006A (es) 2017-12-22 2020-07-13 Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.

Country Status (14)

Country Link
US (1) US20220315621A1 (es)
EP (1) EP3728285A1 (es)
JP (2) JP2021506904A (es)
KR (1) KR20200104349A (es)
CN (1) CN111741965A (es)
AR (1) AR114044A1 (es)
AU (2) AU2018392093B2 (es)
BR (1) BR112020012761A2 (es)
CA (1) CA3086189A1 (es)
IL (1) IL275506A (es)
MA (1) MA51316A (es)
MX (3) MX2020006608A (es)
TW (1) TW201938172A (es)
WO (1) WO2019126761A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2806877T3 (pl) 2012-01-23 2020-06-01 Sage Therapeutics, Inc. Formulacje neuroaktywnego steroidu zawierające kompleks allopregnanolonu i eteru sulfobutylowego beta-cyklodekstryny
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
DK3224269T3 (da) 2014-11-27 2020-05-25 Sage Therapeutics Inc Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser
TWI808945B (zh) 2016-08-23 2023-07-21 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
EP3737687A1 (en) 2018-01-12 2020-11-18 Sage Therapeutics, Inc. Aza-, oxa and thia-pregnan-20-one-3.alpha.-ol compounds for use in treating cns disorders
WO2019154247A1 (zh) * 2018-02-11 2019-08-15 江苏豪森药业集团有限公司 甾族类衍生物调节剂、其制备方法和应用
AU2019357040A1 (en) 2018-10-12 2021-05-20 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
BR112021010996A2 (pt) 2018-12-05 2021-08-31 Sage Therapeutics, Inc. Esteroides neuroativos e seus métodos de uso
AU2020205368A1 (en) * 2019-01-08 2021-08-05 Chengdu kanghong pharmaceutical co ltd Steroid compounds, uses and process for preparation therefor
MX2021014515A (es) 2019-05-31 2022-03-22 Sage Therapeutics Inc Esteroides neuroactivos y composiciones de estos.
JP2022538301A (ja) 2019-06-27 2022-09-01 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を治療するための組成物及び方法
MX2021015942A (es) * 2019-06-27 2022-04-18 Sage Therapeutics Inc Composiciones y métodos para tratar trastornos del snc.
BR112021026447A2 (pt) * 2019-06-27 2022-04-12 Sage Therapeutics Inc Composições e métodos para tratamento de distúrbios de cns
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1380246A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy-androstanes and esters thereof
DK134348C (da) * 1973-11-30 1977-03-21 Schering Ag Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner
IL48628A0 (en) * 1974-12-23 1976-02-29 Schering Ag D-homo-20-keto-pregnanes and process for their manufactur
GB1570394A (en) * 1976-01-06 1980-07-02 Glaxo Lab Ltd 11-acyloxy-3-hydroxy steroids
GB1581234A (en) * 1976-04-05 1980-12-10 Glaxo Operations Ltd 11a - amino - 3a - hydroxysteroids
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
AU3967297A (en) * 1996-08-01 1998-02-25 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
JP6470258B2 (ja) * 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法

Also Published As

Publication number Publication date
US20220315621A1 (en) 2022-10-06
JP2021506904A (ja) 2021-02-22
AR114044A1 (es) 2020-07-15
TW201938172A (zh) 2019-10-01
AU2018392093A1 (en) 2020-07-09
BR112020012761A2 (pt) 2021-02-17
CN111741965A (zh) 2020-10-02
AU2018392093B2 (en) 2024-02-01
IL275506A (en) 2020-08-31
EP3728285A1 (en) 2020-10-28
CA3086189A1 (en) 2019-06-27
MX2020006608A (es) 2020-11-06
RU2020123930A (ru) 2022-01-26
AU2023285947A1 (en) 2024-01-25
WO2019126761A1 (en) 2019-06-27
MA51316A (fr) 2020-10-28
JP2023119042A (ja) 2023-08-25
KR20200104349A (ko) 2020-09-03
MX2023002006A (es) 2023-02-27
RU2020123930A3 (es) 2022-02-04

Similar Documents

Publication Publication Date Title
MX2023002006A (es) Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
MX2023005098A (es) Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central.
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020013014A (es) N-(fenilsulfonil)benzamidas y compuestos relacionados como inhibidores de bcl-2.
MX2021004492A (es) Composiciones para el tratamiento de trastornos del snc.
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
MX2021006902A (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infeccion virica.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
MX2022005160A (es) Oxisteroles y metodos de uso de los mismos.
MX2020010690A (es) Oxiesteroles y metodos de uso de los mismos.
NZ731095A (en) Compositions and methods for treating cns disorders
EP4316591A3 (en) Oxysterols and methods of use thereof
JOP20180092A1 (ar) مثبطات hiv بروتياز
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
PH12017501422A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
PH12019500568A1 (en) Dopamine-b-hydroxylase inhibitors
WO2016164763A8 (en) Compositions and methods for treating cns disorders
ZA202006071B (en) Antiproliferation compounds and uses thereof
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2020008746A (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevencion del cancer de higado.
MX2021015942A (es) Composiciones y métodos para tratar trastornos del snc.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2021007258A (es) Composiciones de esparsentan amorfas.